Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patient Voices Swayed FDA's Imlygic Review Team

Executive Summary

Testimony from patients about the cosmetic and psychological advantages of seeing melanoma lesions shrink was a key element in agency's decision to offer full approval to Amgen's talimogene laherparepvec despite serious concerns about the clinical meaning of the pivotal trial's durable response rate endpoint.

Advertisement

Related Content

Case Studies In FDA's Regulatory Interpretation Of Clinical Trials
Choice Of Regulatory Pathway Is Key Inflection Point In Drug Reviews
Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development
Does Imlygic Make The Case For FDA Oncology Center Of Excellence?
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track
Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register